InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2026-01-30 | Gilbert Cisneros(D-CA31) | house | Purchase | $1,001 - $15,000 |
| 2025-05-15 | Rob Bresnahan(R-PA08) | house | Purchase | $1,001 - $15,000 |
| 2025-04-08 | Rob Bresnahan(R-PA08) | house | Sale | $1,001 - $15,000 |
| 2025-02-25 | Rob Bresnahan(R-PA08) | house | Purchase | $1,001 - $15,000 |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenues | $732.9M+12.3% | $652.6M-27.4% | $899.3M+85.4% | $485.1M+1.8% | $476.3M |
| Cost of sales, excluding amortization and impairment of acquired intangible assets | $2.40B+4.1% | $2.31B-8.8% | $2.53B+11.2% | $2.28B+8.0% | $2.11B |
| Research and development | $1.78B-10.2% | $1.98B-19.0% | $2.45B+9.6% | $2.23B-10.8% | $2.50B |
| Acquired in-process research and development, upfront and milestone expense | $471.8M+667.2% | $61.5M+270.5% | $16.6M | — | — |
| Selling, general and administrative | $2.43B+1.2% | $2.40B-5.7% | $2.55B+6.1% | $2.40B-10.1% | $2.67B |
| Amortization and impairment of acquired intangible assets | $515.0M+15.3% | $446.7M+85.7% | $240.6M-34.2% | $365.9M-58.5% | $881.3M |
| Collaboration profit sharing/(loss reimbursement) | $290.2M+14.1% | $254.4M+16.3% | $218.8M+3056.8% | -$7.4M-202.8% | $7.2M |
| (Gain) loss on fair value remeasurement of contingent consideration | $33.6M+21.3% | $27.7M | $0+100.0% | -$209.1M-312.4% | -$50.7M |
| Impairment of ROU asset | $52.9M | $0 | $0 | — | — |
| Restructuring charges | $48.6M+60.9% | $30.2M-86.2% | $218.8M+66.9% | $131.1M | $0 |
| Gain on sale of priority review voucher, net | $0+100.0% | -$88.6M | $0 | $0 | — |
| Other (income) expense, net | $305.6M-11.1% | $343.6M+8.9% | $315.5M+391.6% | -$108.2M-109.9% | $1.10B |
| Total cost and expense | $8.33B+7.3% | $7.77B-9.0% | $8.54B+29.7% | $6.58B-28.7% | $9.24B |
| Income before income tax (benefit) expense | $1.56B-18.3% | $1.91B+47.0% | $1.30B | — | — |
| Income tax (benefit) expense | $263.6M-3.7% | $273.8M+102.4% | $135.3M-78.6% | $632.8M+1105.3% | $52.5M |
| Net income | $1.29B-20.8% | $1.63B+40.5% | $1.16B-60.8% | $2.96B+71.4% | $1.73B |
| Net income attributable to noncontrolling interests, net of tax | $0 | $0-100.0% | $400K | — | — |
| Net income attributable to Biogen Inc. | $1.29B-20.8% | $1.63B+40.6% | $1.16B-61.9% | $3.05B+95.8% | $1.56B |
| Basic earnings per share attributable to Biogen Inc. (in dollars per share) | $9K-21.2% | $11K+39.8% | $8K-100.0% | $21.0M+100.8% | $10.4M |
| Diluted earnings per share attributable to Biogen Inc. (in dollars per share) | $9K-21.4% | $11K+40.3% | $8K-100.0% | $20.9M+100.7% | $10.4M |
| Weighted-average number of common shares outstanding (in shares) | $147K+0.6% | $146K+0.6% | $145K-99.9% | $145.3M | — |
| Diluted earnings per share attributable to Biogen Inc. (in shares) | $147K+0.8% | $146K+0.2% | $146K-99.9% | $146.0M-99.9% | $149.60B |
| Product revenue, net | |||||
| Revenues | $732.9M+12.3% | $652.6M-27.4% | $899.3M+85.4% | $485.1M+1.8% | $476.3M |
| Revenue from anti-CD20 therapeutic programs | |||||
| Revenues | $732.9M+12.3% | $652.6M-27.4% | $899.3M+85.4% | $485.1M+1.8% | $476.3M |
| Alzheimer's collaboration revenue | |||||
| Revenues | $732.9M+12.3% | $652.6M-27.4% | $899.3M+85.4% | $485.1M+1.8% | $476.3M |
| Contract manufacturing, royalty and other revenue | |||||
| Revenues | $732.9M+12.3% | $652.6M-27.4% | $899.3M+85.4% | $485.1M+1.8% | $476.3M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Biogen Inc (BIIB) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Promising ...
Why Biogen Stock Was a Winner on Wednesday
Is It Time To Reassess Biogen (BIIB) After Its Strong One Year Share Price Rally
Biogen Had A Nearly Perfect Sales Sweep, But One Beat Really Stood Out